MCID: HND002
MIFTS: 50

Hand, Foot and Mouth Disease

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Hand, Foot and Mouth Disease

MalaCards integrated aliases for Hand, Foot and Mouth Disease:

Name: Hand, Foot and Mouth Disease 12 74 44 15 17
Vesicular Stomatitis and Exanthem 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10881
ICD9CM 34 074.3
MeSH 44 D006232
NCIt 50 C128439
SNOMED-CT 67 175497008
ICD10 32 B08.4
UMLS 71 C0018572

Summaries for Hand, Foot and Mouth Disease

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Human coxsackievirus A16 or has material basis in Human enterovirus 71, which are transmitted by contaminated fomites, and transmitted by contact with nose and throat secretions, saliva, blister fluid and stool of infected persons. The infection has symptom fever, has symptom poor appetite, has symptom malaise, has symptom sore throat, has symptom painful sores in the mouth, and has symptom skin rash on the palms of the hands and soles of the feet.

MalaCards based summary : Hand, Foot and Mouth Disease, also known as vesicular stomatitis and exanthem, is related to exanthem and encephalitis, and has symptoms including fever, poor appetite and sore throat. An important gene associated with Hand, Foot and Mouth Disease is SCARB2 (Scavenger Receptor Class B Member 2), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Herpes simplex virus 1 infection. The drugs Mannitol and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and brain, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 74 Hand, foot, and mouth disease (HFMD) is a common infection caused by a group of viruses. It typically... more...

Related Diseases for Hand, Foot and Mouth Disease

Diseases related to Hand, Foot and Mouth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 367)
# Related Disease Score Top Affiliating Genes
1 exanthem 31.8 IL6 IL10 IFNG
2 encephalitis 31.3 TLR3 IL6 IL10 DDX58 AQP4
3 stomatitis 31.1 IL6 IL10 IFNG DDX58
4 chickenpox 31.1 IL6 IL10 IFNG
5 poliomyelitis 31.0 TLR3 SCARB2 IL10 IFNG DDX58
6 myelitis 31.0 IL6 IL10 AQP4
7 dermatitis 31.0 IL6 IL13 IL10 IFNG
8 disease by infectious agent 30.9 TLR7 TLR4 MIR221 IL6 IL10 IFNG
9 myocarditis 30.9 TLR4 TLR3 IL6 IL10 IFNG
10 herpangina 30.8 TLR7 TLR4 TLR3 IL6 IL10 IFNG
11 viral encephalitis 30.7 TLR3 IL6 IL10
12 chorioretinitis 30.7 IL6 IL10 IFNG
13 transverse myelitis 30.6 IL6 IL10 AQP4
14 aphthous stomatitis 30.6 TLR4 IL6 IL10 IFNG
15 japanese encephalitis 30.5 TLR7 TLR3 DDX58
16 rhinitis 30.5 IL6 IL13 IL10 IFNG
17 graft-versus-host disease 30.4 IL6 IL10 IFNG
18 purpura 30.4 IL6 IL10 IFNG
19 herpes zoster 30.4 TLR3 IL10 IFNG
20 bronchopneumonia 30.4 TLR4 IL6 IL10
21 acute transverse myelitis 30.4 IL6 IL10 AQP4
22 posterior uveitis 30.4 IL6 IL13 IFNG
23 endocarditis 30.4 IL6 IL10 IFNG
24 measles 30.4 TLR7 TLR4 TLR3 IL6 IFNG DDX58
25 dermatitis, atopic 30.4 TLR4 IL6 IL13 IL10 IFNG
26 mumps 30.3 TLR3 IL6 IL10 IFNG
27 diarrhea 30.3 TLR4 IL6 IL13 IL10 IFNG
28 plague 30.3 TLR4 IL6 IL10 DDX58
29 respiratory failure 30.3 TLR4 IL6 IL13 IL10
30 tetanus 30.2 IL6 IL13 IL10 IFNG
31 appendicitis 30.2 TLR4 IL6 IL10 IFNG
32 chlamydia 30.2 TLR4 IL6 IL10 IFNG
33 hepatitis a 30.2 TLR4 TLR3 IL10 IFNG
34 brain edema 30.1 IL6 IFNG AQP4
35 meningitis 30.1 TLR4 IL6 IL13 IL10 IFNG AQP4
36 conjunctivitis 30.1 TLR3 IL6 IL13 IL10 IFNG
37 skin disease 30.0 S100B IL6 IL13 IL10 IFNG DDX58
38 tonsillitis 30.0 TLR4 TLR3 IL6 IL10 IFNG
39 viral hepatitis 30.0 TLR4 TLR3 IL6 IL10 IFNG
40 nervous system disease 29.7 TLR4 MIR221 IL6 IL10 IFNG AQP4
41 viral infectious disease 29.6 TLR7 TLR4 TLR3 OAS1 IL6 IL13
42 bronchiolitis 29.6 TLR7 TLR4 TLR3 IL6 IL13 IL10
43 mouth disease 29.2 TLR7 TLR4 TLR3 SCARB2 S100B OAS1
44 pulmonary edema 10.9
45 aseptic meningitis 10.9
46 cytokine deficiency 10.6
47 hyperglycemia 10.6
48 erythema multiforme 10.5
49 ocular motor apraxia 10.5
50 rhabdomyosarcoma 10.5

Graphical network of the top 20 diseases related to Hand, Foot and Mouth Disease:



Diseases related to Hand, Foot and Mouth Disease

Symptoms & Phenotypes for Hand, Foot and Mouth Disease

Symptoms:

12
  • fever
  • poor appetite
  • sore throat
  • malaise
  • painful sores in the mouth
  • skin rash on the palms of the hands

MGI Mouse Phenotypes related to Hand, Foot and Mouth Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 AQP4 DDX58 FUBP1 GBA IFNG IL10
2 homeostasis/metabolism MP:0005376 10.1 ANKRD17 AQP4 DDX58 GBA IFNG IL10
3 immune system MP:0005387 9.93 AQP4 DDX58 FUBP1 GBA IFNG IL10
4 mortality/aging MP:0010768 9.8 ANKRD17 AQP4 DDX58 FUBP1 GBA IFNG
5 respiratory system MP:0005388 9.28 AQP4 FUBP1 GBA IFNG IL10 IL13

Drugs & Therapeutics for Hand, Foot and Mouth Disease

Drugs for Hand, Foot and Mouth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
2
Ribavirin Approved Phase 4 36791-04-5 37542
3 Anti-Infective Agents Phase 4
4 Antibodies, Blocking Phase 4
5 Antimetabolites Phase 4
6 Antiviral Agents Phase 4
7 Immunoglobulins Phase 4
8 Antibodies Phase 4
9 Vaccines Phase 4
10 Immunologic Factors Phase 4
11
Ibuprofen Approved Phase 2 15687-27-1 3672
12
Acetaminophen Approved Phase 2 103-90-2 1983
13
Sucralfate Approved Phase 2 54182-58-0
14
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 2 7487-88-9 24083
15
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
16 Pharmaceutical Solutions Phase 2
17 Anti-Inflammatory Agents Phase 2
18 Gastrointestinal Agents Phase 2
19 Analgesics, Non-Narcotic Phase 2
20 Anti-Ulcer Agents Phase 2
21 Antacids Phase 2
22 Cyclooxygenase Inhibitors Phase 2
23 Anti-Inflammatory Agents, Non-Steroidal Phase 2
24 Antirheumatic Agents Phase 2
25 Antipyretics Phase 2
26 Anticonvulsants Phase 2
27 Anesthetics Phase 2
28 Retinol palmitate Phase 2
29 retinol Phase 2
30 Hormones Phase 2
31 Tocolytic Agents Phase 2
32 Calcium, Dietary Phase 2
33 Analgesics Phase 2
34 calcium channel blockers Phase 2
35 Anti-Arrhythmia Agents Phase 2
36
Calcium Nutraceutical Phase 2 7440-70-2 271
37
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
38
Suramin Investigational Phase 1 145-63-1 5361
39 Antiparasitic Agents Phase 1
40 Anthelmintics Phase 1
41 Antiprotozoal Agents Phase 1
42
Prednisolone Approved, Vet_approved 50-24-8 5755
43 Prednisolone acetate Approved, Vet_approved 52-21-1
44
Prednisolone phosphate Approved, Vet_approved 302-25-0
45
Methylprednisolone Approved, Vet_approved 83-43-2 6741
46
Methylprednisolone hemisuccinate Approved 2921-57-5
47
Vitamin C Approved, Nutraceutical 50-81-7 5785 54670067
48
Prednisolone hemisuccinate Experimental 2920-86-7
49 Vitamin B Complex
50 Vitamins

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months Unknown status NCT02889497 Phase 4
2 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Unknown status NCT03296410 Phase 4
3 Study on Immunogenicity of Inactivated Enterovirus 71 (EV71) Vaccine (Human Diploid Cell, KMB-17) in Large-scale Healthy Children in China Unknown status NCT03240744 Phase 4
4 Effectiveness and Safety of Inactivated EV71 Vaccine (Human Diploid Cell) in 6-71 Months Children: an Open-label Controlled Phase Ⅳ Clinical Study Completed NCT03001986 Phase 4
5 A Opened,Randomized and Controlled Trial to Evaluate the Immunity and Safety of Sequential Vaccination of Two Different Commercial EV71 Inactived Vaccines in Healthy Infants Aged 6-35 Months Completed NCT03873740 Phase 4
6 A Phase IV Open-labelled, Single-centered, Stratified-randomized Clinical Trial in Zhejiang Province to Evaluate the Safety and Immunogenicity of EV71 Vaccine Developed by Sinovac Biotech Co., Ltd. Completed NCT03278132 Phase 4
7 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Recombinant Hepatitis B Vaccine/Group A Meningococcal Polysaccharide Vaccine Completed NCT03274102 Phase 4
8 Effect and Safety of Xiao'er Jiebiao Oral Liquid in Combination With Standard Treatment on Hand-foot-mouth Disease in Pediatric Patients Completed NCT02328651 Phase 4 Ribavirin plus Xiao'er jiebiao oral liquid;Ribavirin
9 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine Recruiting NCT04111432 Phase 4
10 Multiple Centers, Randomized, and Control Trail on the Immunogenicity and Safety of the Simultaneously Vaccination of Inactivated Enterovirus 71 Vaccine (EV71) and Seasonal Influenza Vaccine(SIV) Recruiting NCT04133584 Phase 4
11 Phase Ⅳ Clinical Trial, to Evaluate the Efficacy of the Enterovirus 71 (EV71) Inactivated Vaccine and Its Correlation With EV71 Antibody Level Active, not recruiting NCT03903926 Phase 4
12 A Phase IV Clinical Trial for Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71: A Multicenter, Case-control Study. Enrolling by invitation NCT03582761 Phase 4
13 Three Batches Consistency, Immunity Duration and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China Not yet recruiting NCT03893747 Phase 4
14 A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months Completed NCT01508247 Phase 3
15 A Multicentered, Double - Blind, Randomized, and Placebo - Controlled Clinical Trial With Inactivated Enterovirus Type 71 (EV71) Vaccines Completed NCT01507857 Phase 3
16 Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine: A Double-blind, Randomized and Controlled Trial Completed NCT01636245 Phase 3
17 A Phase III Clinical Trial With Randomized, Double-blinded, Controlled Design as Well as Bridging Design to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Children Aged 36-71 Months Completed NCT03909074 Phase 3
18 Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial Unknown status NCT03241030 Phase 2 Sucralfate;Acetaminophen;Ibuprofen
19 A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Magnesium Sulfate for the Management of Severe Hand, Foot and Mouth Disease With Autonomic Nervous System Dysregulation in Vietnamese Children. Completed NCT01940250 Phase 2 Magnesium Sulphate;Sterile water
20 A Phase II Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants Completed NCT01512706 Phase 2
21 A Randomized, Open, Phase I/II to Evaluate the Inactivated EV 71 Vaccine Safety in Healthy Adults Followed by Safety and Immunogenicity Administered in 2 Consecutive Doses, 1 Month Apart Among Child Aged 6 to 71 Months. Completed NCT04467541 Phase 1, Phase 2
22 A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium in Healthy Chinese Adults Unknown status NCT03804749 Phase 1 suramin sodium
23 Phase I, Double Blind, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of a Prophylactic Vaccine Against Enterovirus Infection in Healthy Adults Completed NCT01376479 Phase 1
24 A Phase Ia Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children Completed NCT01267903 Phase 1
25 A Phase I Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Adults, Children and Infants Completed NCT01391494 Phase 1
26 A Phase Ib Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01313715 Phase 1
27 A Blind, Randomized and Placebo-controlled Clinical Trial With Inactivated Enterovirus Type 71 Vaccines in Healthy Children. Completed NCT01273246 Phase 1
28 A Randomized, Double-blind, Placebo-controlled, Phase 1 Clinical Trial to Investigate the Safety and Immunogenicity of CJ-40010 After Administration in Healthy Subjects Recruiting NCT04182932 Phase 1
29 A Randomized, Double-blind, Placebo-controlled, Phase 1 Clinical Trial to Investigate the Safety and Immunogenicity of High-dose IN-B001 After Administration in Healthy Subjects Not yet recruiting NCT04637919 Phase 1
30 A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Unknown status NCT01182025 Xiyanping Injection;Xiyanping Injection with western medicine
31 A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease Unknown status NCT01145664 Herbal concentrate-granules plus western therapy;Reduning Injection plus western therapy;Western therapy
32 A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Unknown status NCT01175915
33 An Open-labelled, Multicentered, Follow-up Study for a Phase III, Efficacy Trial to Evaluate the Two-year Efficacy, Safety, and Immune Persisitence of Inactivated Enterovirus Type 71 (EV71) Vaccine Completed NCT02001233
34 Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children Completed NCT01255124
35 A Prospective Cohort Study Evaluating Prognostic Indicators and Sequelae Following Severe Hand Foot and Mouth Disease Completed NCT02066714
36 Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study Completed NCT01769794 Western therapy;JET;Placebo(for JET)
37 A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Completed NCT01182532 TCM Syndrome Differentiation and Treatment
38 A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Severe Type of Hand, Foot, and Mouth Disease Completed NCT01554930 Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge);Xiyanping injection plus western therapy
39 Phase IV, Open-labelled, Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine Completed NCT03281174

Search NIH Clinical Center for Hand, Foot and Mouth Disease

Cochrane evidence based reviews: hand, foot and mouth disease

Genetic Tests for Hand, Foot and Mouth Disease

Anatomical Context for Hand, Foot and Mouth Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Hand, Foot and Mouth Disease:

19
Skin

MalaCards organs/tissues related to Hand, Foot and Mouth Disease:

40
Skin, T Cells, Brain, Endothelial, Neutrophil, Placenta, Monocytes

Publications for Hand, Foot and Mouth Disease

Articles related to Hand, Foot and Mouth Disease:

(show top 50) (show all 2223)
# Title Authors PMID Year
1
Sulfonated azo dyes enhance the genome release of enterovirus A71 VP1-98K variants by preventing the virions from being trapped by sulfated glycosaminoglycans at acidic pH. 61
33422703 2021
2
An epidemiological surveillance of hand foot and mouth disease in paediatric patients and in community: A Singapore retrospective cohort study, 2013-2018. 61
33566802 2021
3
Spatiotemporal characteristics and meteorological determinants of hand, foot and mouth disease in Shaanxi Province, China: a county-level analysis. 61
33596869 2021
4
Polymorphisms in the DC-SIGN gene and their association with the severity of hand, foot, and mouth disease caused by enterovirus 71. 61
33590343 2021
5
DNA Methylation and SNP in IFITM3 are correlated with patients with hand, foot and mouth disease caused by enterovirus 71. 61
33596480 2021
6
Antiviral peptides against Enterovirus A71 causing hand, foot and mouth disease. 61
33171280 2021
7
Characterization of oral virome and microbiome revealed distinctive microbiome disruptions in paediatric patients with hand, foot and mouth disease. 61
33608551 2021
8
Prevalence of recessive infection of pathogens of hand, foot, and mouth disease in healthy people in China: A meta-analysis. 61
33607859 2021
9
[A case of hand, foot and mouth disease in adults who first diagnosed with conjunctivitis]. 61
33541056 2021
10
Daily mean temperature and HFMD: risk assessment and attributable fraction identification in Ningbo China. 61
33547422 2021
11
Construction and characterization of an infectious cDNA clone of enterovirus 71: a rapid method for rescuing infectious virus based on stable cells expressing T7 polymerase. 61
33423081 2021
12
Recent advances in the understanding of enterovirus A71 infection: a focus on neuropathogenesis. 61
33183118 2021
13
Natural intertypic and intratypic recombinants of enterovirus 71 from mainland China during 2009-2018: a complete genome analysis. 61
33575934 2021
14
Molecular epidemiology and recombination of Enterovirus A71 in mainland China from 1987 to 2017. 61
33608776 2021
15
A uniform quantitative enzyme-linked immunosorbent assay for Coxsackievirus A16 antigen in vaccine. 61
32750255 2021
16
Ginsenoside Rb1 is an immune-stimulatory agent with antiviral activity against enterovirus 71. 61
32980486 2021
17
Forecasting hand-foot-and-mouth disease cases using wavelet-based SARIMA-NNAR hybrid model. 61
33544752 2021
18
Regional-level risk factors for severe hand-foot-and-mouth disease: an ecological study from mainland China. 61
33419405 2021
19
Leading Enterovirus Genotypes Causing Hand, Foot, and Mouth Disease in Guangzhou, China: Relationship with Climate and Vaccination against EV71. 61
33401757 2021
20
Forecast and early warning of hand, foot, and mouth disease based on meteorological factors: Evidence from a multicity study of 11 meteorological geographical divisions in mainland China. 61
33069698 2021
21
Trend analysis and forecast of daily reported incidence of hand, foot and mouth disease in Hubei, China by Prophet model. 61
33446859 2021
22
Assessing the vaccine effectiveness for hand, foot, and mouth disease in Guangzhou, China: a time-series analysis. 61
32530733 2021
23
EV71 vaccination impact on the incidence of encephalitis in patients with hand, foot and mouth disease. 61
33522390 2021
24
Immune Mechanism of Hand Foot and Mouth Disease Sepsis. 61
32683536 2021
25
Exploring the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Glycyrrhizic and Glycyrrhetinic Acids. 61
33505216 2021
26
How to improve infectious disease prediction by integrating environmental data: an application of a novel ensemble analysis strategy to predict HFMD. 61
33446283 2021
27
Amino acid substitutions in VP2, VP1, and 2C attenuate a Coxsackievirus A16 in mice. 61
33271234 2021
28
Recombinant Human SCARB2 Expressed in Escherichia coli and its Potential in Enterovirus 71 Blockage. 61
33424194 2021
29
Efficacy of an inactivated bivalent vaccine for enterovirus 71 and coxsackievirus A16 in mice immunized intradermally. 61
33342637 2021
30
Risk factors of hand, foot, and mouth disease caused by Coxsackievirus A6 in children under 6 years of age in Tianjin, China: a case-control study. 61
33518630 2021
31
Identifying pre-outbreak signals of hand, foot and mouth disease based on landscape dynamic network marker. 61
33446118 2021
32
Development of Three-Dimensional Human Intestinal Organoids as a Physiologically Relevant Model for Characterizing the Viral Replication Kinetics and Antiviral Susceptibility of Enteroviruses. 61
33477611 2021
33
Efficacy of Coxsackievirus A5 Vaccine Candidates in an Actively Immunized Mouse Model. 61
33408178 2021
34
Antivirals blocking entry of enteroviruses and therapeutic potential. 61
33451326 2021
35
[Atypical hand, foot and mouth disease in adults: A note on 6 cases]. 61
32654792 2020
36
Distribution of enterovirus genotypes detected in clinical samples in Hungary, 2010-2018. 61
33295885 2020
37
Spatiotemporal analysis of hand, foot and mouth disease data using time-lag geographically-weighted regression. 61
33461279 2020
38
Epidemiological characteristics and trends of notifiable infectious diseases in China from 1986 to 2016. 61
33214900 2020
39
Coxsackievirus A6-induced Hand-Foot-and-Mouth Disease Mimicking Stevens-Johnson Syndrome in an Immunocompetent Adult. 61
32757503 2020
40
Enterovirus 71 induces neural cell apoptosis and autophagy through promoting ACOX1 downregulation and ROS generation. 61
32434419 2020
41
Enterovirus genomic load and disease severity among children hospitalised with hand, foot and mouth disease. 61
33161231 2020
42
The temporal characteristics of the lag-response relationship and related key time points between ambient temperature and hand, foot and mouth disease: A multicity study from mainland China. 61
32836135 2020
43
Early Evidence of Inactivated Enterovirus 71 Vaccine Impact Against Hand, Foot, and Mouth Disease in a Major Center of Ongoing Transmission in China, 2011-2018: A Longitudinal Surveillance Study. 61
31879754 2020
44
Coxsackieviruses A6 and A16 associated with hand, foot, and mouth disease in Vietnam, 2008-2017: Essential information for rational vaccine design. 61
33223308 2020
45
Basic Reproduction Number of Enterovirus 71 Coxsackievirus A16 and A6: Evidence from Outbreaks of Hand, Foot and Mouth Disease in China between 2011 and 2018. 61
33320199 2020
46
Is choriocapillaris the early target in acute maculopathy secondary to hand, foot, and mouth disease? A case report. 61
33325253 2020
47
Abnormalities of ILC1 in children with hand, foot and mouth disease during enterovirus 71 infection. 61
33011521 2020
48
[Material basis and mechanism of Xiao'er Resuqing Oral Liquid on hand, foot and mouth disease based on network pharmacology and molecular docking]. 61
33496115 2020
49
Bioinformatics Analysis of Key micro-RNAs and mRNAs under the Hand, Foot, and Mouth Disease Virus Infection. 61
33574876 2020
50
Epidemical and etiological study on hand, foot and mouth disease following EV-A71 vaccination in Xiangyang, China. 61
33262488 2020

Variations for Hand, Foot and Mouth Disease

Expression for Hand, Foot and Mouth Disease

Search GEO for disease gene expression data for Hand, Foot and Mouth Disease.

Pathways for Hand, Foot and Mouth Disease

Pathways related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 TLR7 TLR4 TLR3 OAS1 IL6 IL10
2 12.73 TLR3 OAS1 IL6 IFNG DDX58
3
Show member pathways
12.62 TLR7 TLR4 TLR3 OAS1 IL6 IFNG
4
Show member pathways
12.51 TLR4 IL6 IL13 IL10 IFNG
5 12.4 TLR7 TLR3 OAS1 IL10 IFNG DDX58
6
Show member pathways
12.35 IL6 IL13 IL10 IFNG
7
Show member pathways
12.25 TLR4 TLR3 IL6 IFNG
8
Show member pathways
12.2 TLR7 TLR4 TLR3 IL6
9 12.17 TLR4 IL6 IL10 IFNG
10
Show member pathways
12.17 OAS1 IL6 IL13 IL10 IFNG
11
Show member pathways
12.12 TLR7 TLR4 IL6 IFNG
12 12.1 IL6 IL13 IL10 AQP4
13 12.05 TLR7 TLR4 TLR3 IL6 IFNG
14
Show member pathways
11.93 TLR7 TLR4 TLR3 IL13
15 11.89 TLR4 IL6 IFNG AQP4
16 11.81 TLR4 IL6 IFNG
17 11.79 TLR4 IL6 IL10 IFNG
18 11.76 TLR7 TLR4 TLR3
19 11.73 IL6 IL13 IFNG
20 11.72 IL13 IL10 IFNG
21 11.68 TLR4 IL6 IL10
22 11.63 TLR7 IL6 IL10 IFNG
23 11.62 TLR4 IL6 IL10
24
Show member pathways
11.51 TLR7 TLR4 TLR3 IL6 IFNG
25 11.47 IL6 IL13 IL10
26 11.42 IL13 IL10 IFNG
27 11.32 TLR4 IL6 IL10 IFNG
28 11.3 IL6 IL10 IFNG
29 11.27 TLR4 IL6 IL10
30 11.21 IL6 IL13 IFNG
31 11.09 IL13 IL10 IFNG
32
Show member pathways
10.98 TLR7 TLR4 TLR3 IL6 IL10 IFNG
33 10.74 IL6 IL13
34 10.72 IL6 IL13 IL10 IFNG

GO Terms for Hand, Foot and Mouth Disease

Cellular components related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 TLR3 S100B MIR576 MIR221 IL6 IL13
2 endosome membrane GO:0010008 9.02 TLR7 TLR4 TLR3 SCARB2 AQP4

Biological processes related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.14 TLR7 TLR4 TLR3 OAS1 DDX58 ANKRD17
2 innate immune response GO:0045087 10.07 TLR7 TLR4 TLR3 S100B OAS1 DDX58
3 inflammatory response GO:0006954 10.04 TLR7 TLR4 TLR3 IL6 IL13
4 positive regulation of gene expression GO:0010628 10.02 TLR4 TLR3 IL6 IL13 IFNG FUBP1
5 immune response GO:0006955 10 TLR7 TLR4 TLR3 IL6 IL13 IL10
6 defense response to bacterium GO:0042742 9.98 TLR4 TLR3 IL10 ANKRD17
7 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.94 TLR4 TLR3 S100B ANKRD17
8 negative regulation of inflammatory response GO:0050728 9.91 MIR221 IL13 IL10 GBA
9 response to virus GO:0009615 9.89 TLR3 OAS1 IFNG DDX58
10 positive regulation of inflammatory response GO:0050729 9.88 TLR7 TLR4 TLR3 IFNG
11 defense response to virus GO:0051607 9.88 TLR7 TLR3 OAS1 IL6 IFNG DDX58
12 cellular response to interferon-gamma GO:0071346 9.86 TLR4 TLR3 AQP4
13 negative regulation of interleukin-6 production GO:0032715 9.85 TLR4 IL10 GBA
14 cellular response to mechanical stimulus GO:0071260 9.85 TLR7 TLR4 TLR3 IL13
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.84 TLR7 TLR4 TLR3
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 MIR221 IL6 IL13 IFNG
17 positive regulation of interferon-gamma production GO:0032729 9.83 TLR7 TLR4 TLR3
18 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.83 TLR7 TLR4 TLR3
19 positive regulation of interleukin-1 beta production GO:0032731 9.81 TLR4 IL6 IFNG
20 positive regulation of cytokine production GO:0001819 9.81 TLR3 IL10 IFNG
21 toll-like receptor signaling pathway GO:0002224 9.8 TLR7 TLR4 TLR3
22 positive regulation of interleukin-12 production GO:0032735 9.79 TLR4 TLR3 IFNG
23 positive regulation of interleukin-10 production GO:0032733 9.79 TLR4 IL6 IL13
24 positive regulation of JAK-STAT cascade GO:0046427 9.77 MIR221 IL6 IL10
25 positive regulation of macrophage activation GO:0043032 9.74 TLR4 IL13 IL10
26 positive regulation of immunoglobulin production GO:0002639 9.73 IL6 IL13 IL10
27 positive regulation of interferon-beta production GO:0032728 9.73 TLR7 TLR4 TLR3 DDX58
28 positive regulation of tumor necrosis factor production GO:0032760 9.72 TLR4 TLR3 IL6 IFNG DDX58
29 I-kappaB phosphorylation GO:0007252 9.69 TLR7 TLR4 TLR3
30 positive regulation of signaling receptor activity GO:2000273 9.68 IL10 IFNG
31 macrophage activation GO:0042116 9.68 TLR4 IL13
32 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.67 MIR221 IL10
33 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 TLR4 IL10 IFNG
34 microglial cell activation GO:0001774 9.67 TLR7 TLR3 IL13 IFNG
35 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.65 TLR4 TLR3
36 detection of virus GO:0009597 9.63 TLR3 DDX58
37 regulation of dendritic cell cytokine production GO:0002730 9.58 TLR4 TLR3
38 positive regulation of interferon-alpha production GO:0032727 9.56 TLR7 TLR4 TLR3 DDX58
39 positive regulation of interleukin-8 production GO:0032757 9.55 TLR7 TLR4 TLR3 IL6 DDX58
40 positive regulation of chemokine production GO:0032722 9.35 TLR7 TLR4 TLR3 IL6 IFNG
41 positive regulation of interleukin-6 production GO:0032755 9.1 TLR7 TLR4 TLR3 IL6 IFNG DDX58

Molecular functions related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.46 TLR7 TLR4 TLR3 SCARB2
2 cytokine activity GO:0005125 9.26 IL6 IL13 IL10 IFNG
3 double-stranded RNA binding GO:0003725 8.92 TLR7 TLR3 OAS1 DDX58

Sources for Hand, Foot and Mouth Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....